Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director | June 17, 2026 | June 22, 2026 |
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Director | March 24, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16 | Direct | 20,275 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
Pyxis Oncology, Inc.
Report date March 24, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-03-24 | Direct | 45,867 |
Reported balance
After 2026-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-24 · Grant · Acquired 45,867 · Balance 45,867 F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 20,275 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000905148-26-003035 · form4.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2036-06-16 F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:35 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 9,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002560 · form4.xml · nonDerivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,366 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 21:04 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 45,867 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001193125-26-124313 · ownership.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,867 Underlying: Common Stock · 45,867 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:49 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 20,275 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000905148-25-002172 · form4.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2035-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 12:58 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 36,979 | $0.98 Strike: $0.98 | $36,239.42 |
DisclosureSEC source: 0000950170-25-048895 · ownership.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,979 Underlying: Common Stock · 36,979 shares Expires 2035-03-31 F1 · derivative.exercise_date: The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 21:00 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070833 · ownership.xml · nonDerivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 20:54 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 69,760 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0000950170-24-030865 · ownership.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,760 Underlying: Common Stock · 69,760 shares Expires 2034-03-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in three equal annual installments beginning on the first anniversary of March 12, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:32 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000905148-24-000904 · form4.xml · derivative · entry 1 Palani Santhosh · CIK 0002013475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-03-03 F1 · derivative.exercise_date: The shares subject to the option shall vest in 36 substantially equal monthly installments beginning on March 4, 2024 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.